 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Hearing on Second-Opinion Genetic Testing Highlights Risks of Athena's Exclusive Licensing Practices
January 16, 2013
Hearing on Second-Opinion Genetic Testing Highlights Risks of Athena's Exclusive Licensing Practices
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- USPTO Hearing on Confirmatory Gene Testing Raises Calls for Reform Outside Patent System
February 22, 2012 / Pharmacogenomics Reporter - GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter - US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter